|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...6566676869707172737475...156157» |
- ||| Trial completion: Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) (clinicaltrials.gov) - May 14, 2015
P1, N=52, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed
- DC-TAB / Delta Crystallon
New P2a trial: A Study to Evaluate Safety and Efficacy of DC-TAB in Multiple Sclerosis (clinicaltrials.gov) - May 13, 2015
P2a, N=32, Completed, Sponsor: Delta Crystallon BV
- DC-TAB / Delta Crystallon
New P1 trial: Safety and Dose-finding Study of DC-TAB in Healthy Subjects (clinicaltrials.gov) - May 13, 2015
P1, N=76, Completed, Sponsor: Delta Crystallon BV
- Enrollment open, Trial primary completion date: Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo (clinicaltrials.gov) - May 13, 2015
P=N/A, N=1500, Recruiting, Sponsor: St. Luke's-Roosevelt Hospital Center
Active, not recruiting --> Completed Active, not recruiting --> Recruiting | Trial primary completion date: Mar 2015 --> Mar 2016
- New trial: "MS-Fit": Standardized Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis (clinicaltrials.gov) - May 12, 2015
P=N/A, N=62, Not yet recruiting, Sponsor: University Hospital Inselspital, Berne
- ||| New trial: Chronic Periodontitis and Tooth Loss in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 12, 2015
P=N/A, N=400, Active, not recruiting, Sponsor: University of Birmingham
- ||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed, Combination therapy, Monotherapy: A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants (clinicaltrials.gov) - May 12, 2015
P3, N=228, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting | Trial primary completion date: Mar 2015 --> Mar 2016 Recruiting --> Active, not recruiting
- ||| mavrilimumab (KPL-301) / Kiniksa
Enrollment closed: A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - May 12, 2015
P2, N=400, Active, not recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | dalfampridine / Generic mfg.
Enrollment closed: Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients? (clinicaltrials.gov) - May 12, 2015
P2/3, N=58, Active, not recruiting, Sponsor: London Health Sciences Centre
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Benlysta (belimumab) / GSK
Trial completion: A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector (clinicaltrials.gov) - May 12, 2015
P2b, N=95, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- New trial: Effects of Low Intensity Aerobic Exercise on the Microvascular Endothelial Function of Patients With Type 1 Diabetes (clinicaltrials.gov) - May 12, 2015
P=N/A, N=22, Completed, Sponsor: Instituto Nacional de Cardiologia de Laranjeiras
- || Enrollment closed: Insight Kids: Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - May 12, 2015
P=N/A, N=98, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- | Epratucyn (epratuzumab) / Gilead
Trial completion: Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood (clinicaltrials.gov) - May 12, 2015
P1, N=42, Completed, Sponsor: UCB Biopharma S.P.R.L.
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| BI 655064 / AbbVie, Boehringer Ingelheim
Trial completion: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy (clinicaltrials.gov) - May 12, 2015
P1, N=107, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Enrollment change, Combination therapy: A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage (clinicaltrials.gov) - May 12, 2015
P4, N=429, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Completed | N=618 --> 429
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion: The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor (clinicaltrials.gov) - May 12, 2015
P3, N=30, Completed, Sponsor: Melbourne Health
Recruiting --> Completed | N=618 --> 429 Recruiting --> Completed
- |||| Trial primary completion date: IGIV Study for Chronic ITP Patients Ages 3-70 (clinicaltrials.gov) - May 8, 2015
P3, N=75, Recruiting, Sponsor: Grifols Biologicals Inc.
Recruiting --> Completed Trial primary completion date: Mar 2014 --> Mar 2017
- ||||| vobarilizumab (ALX-0061) / Sanofi
New P2 trial: A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - May 8, 2015
P2, N=300, Not yet recruiting, Sponsor: Ablynx
- New trial: MPC Versus PID for Closed Loop Insulin Delivery (clinicaltrials.gov) - May 8, 2015
P=N/A, N=20, Recruiting, Sponsor: William Sansum Diabetes Center
- New P2 trial: Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms (clinicaltrials.gov) - May 8, 2015
P2, N=30, Not yet recruiting, Sponsor: In Home Closed Loop Study Group
- |||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment open: Evaluate Effects of Personalized Patient Counselling for Enbrel (clinicaltrials.gov) - May 8, 2015
P4, N=300, Recruiting, Sponsor: Amgen
Trial primary completion date: Mar 2014 --> Mar 2017 Not yet recruiting --> Recruiting
- | Humira (adalimumab) / AbbVie
Enrollment open, Trial initiation date, Trial primary completion date: The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients (clinicaltrials.gov) - May 8, 2015
P3, N=30, Recruiting, Sponsor: Heinrich-Heine University, Duesseldorf
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Oct 2014 | Trial primary completion date: Mar 2015 --> Oct 2015
- ||| Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku
Trial completion: Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 8, 2015
P1, N=154, Completed, Sponsor: Celltrion
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Oct 2014 | Trial primary completion date: Mar 2015 --> Oct 2015 Active, not recruiting --> Completed
- Tysabri (natalizumab) / Biogen, Royalty, Fumaderm (dimethyl fumarate) / Biogen
Trial primary completion date: IIT6: Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design (clinicaltrials.gov) - May 7, 2015
P=N/A, N=30, Active, not recruiting, Sponsor: Rocky Mountain MS Research Group, LLC
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Sep 2015
- Biomarker, Trial primary completion date: A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis (clinicaltrials.gov) - May 7, 2015
P=N/A, N=45, Recruiting, Sponsor: John F. Foley, MD
Trial primary completion date: Sep 2014 --> Sep 2015 Trial primary completion date: May 2015 --> May 2016
- New trial: Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening? (clinicaltrials.gov) - May 7, 2015
P=N/A, N=40, Not yet recruiting, Sponsor: University of British Columbia
- rosuvastatin / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: RORAAS: Effects of Rosuvastatin on Carotid Artery Plaques in Patients With Inflammatory Joint Disease (clinicaltrials.gov) - May 7, 2015
P=N/A, N=114, Completed, Sponsor: Diakonhjemmet Hospital
Trial primary completion date: May 2015 --> May 2016 Enrolling by invitation --> Completed | Initiation date: Jan 2010 --> Jan 2013 | Trial primary completion date: Dec 2013 --> Aug 2013
- Trial primary completion date: Acute Effect of Resistance Training in Inflammatory Markers in Women With Rheumatoid Arthritis (clinicaltrials.gov) - May 6, 2015
P4, N=34, Active, not recruiting, Sponsor: Federal University of São Paulo
Enrolling by invitation --> Completed | Initiation date: Jan 2010 --> Jan 2013 | Trial primary completion date: Dec 2013 --> Aug 2013 Trial primary completion date: Mar 2015 --> Jul 2015
- glatiramer acetate / Generic mfg.
Enrollment closed: Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells (clinicaltrials.gov) - May 6, 2015
P=N/A, N=24, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Trial primary completion date: Mar 2015 --> Jul 2015 Recruiting --> Active, not recruiting
- Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment open, Monotherapy: Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 6, 2015
P1, N=30, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| New trial: Sudoscan in Patients With Autoimmune Disorders (clinicaltrials.gov) - May 5, 2015
P=N/A, N=100, Enrolling by invitation, Sponsor: The Catholic University of Korea
- ||||| remtolumab (ABT-122) / AbbVie
New P2 trial, P2 data: Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study (clinicaltrials.gov) - May 5, 2015
P2, N=80, Enrolling by invitation, Sponsor: AbbVie
- Gammanorm (human immune globulin subcutaneous) / Octapharma
Enrollment closed, Trial primary completion date: Immunoglobulin Dosage and Administration Form in CIDP and MMN (clinicaltrials.gov) - May 5, 2015
P=N/A, N=45, Active, not recruiting, Sponsor: Rigshospitalet, Denmark
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Aug 2015
- New trial: Development of a Comprehensive AP Training Curriculum for Adults (clinicaltrials.gov) - May 5, 2015
P=N/A, N=36, Not yet recruiting, Sponsor: University of Virginia
- RSLV-132 / Resolve
Enrollment closed: Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) - May 5, 2015
P2, N=32, Active, not recruiting, Sponsor: Resolve Therapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Aug 2015 Recruiting --> Active, not recruiting
- ||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial completion: Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - May 5, 2015
P1, N=105, Completed, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: Vascular Reactivity in Kidney Disease Patients (clinicaltrials.gov) - May 5, 2015
P=N/A, N=15, Completed, Sponsor: Melbourne Health
Active, not recruiting --> Completed Suspended --> Completed
- |||| Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
Trial primary completion date: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) (clinicaltrials.gov) - May 4, 2015
P3, N=350, Recruiting, Sponsor: CSL Behring
Suspended --> Completed Trial primary completion date: Nov 2015 --> Sep 2016
- |||| dimethyl fumarate / Generic mfg.
Enrollment open, Phase classification, Trial initiation date: Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. (clinicaltrials.gov) - May 4, 2015
P2, N=70, Recruiting, Sponsor: Biogen Idec
Trial primary completion date: Nov 2015 --> Sep 2016 Not yet recruiting --> Recruiting | Phase classification: P3 --> P2 | Initiation date: Mar 2014 --> Feb 2015
- Enrollment open, Enrollment change, Trial primary completion date: Closing the Loop 24/7 in Adolescents With Type 1 Diabetes (clinicaltrials.gov) - May 4, 2015
P=N/A, N=24, Recruiting, Sponsor: University of Cambridge
Not yet recruiting --> Recruiting | Phase classification: P3 --> P2 | Initiation date: Mar 2014 --> Feb 2015 Active, not recruiting --> Recruiting | N=12 --> 24 | Trial primary completion date: May 2015 --> Sep 2015
- New trial: TotCamp: Pilot Study: Intensive Education in a Residential Camp Setting for Families of Young Children With Type 1 Diabetes (clinicaltrials.gov) - May 4, 2015
P=N/A, N=18, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
- | Tavalisse (fostamatinib) / Rigel
New P2 trial: Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy (clinicaltrials.gov) - May 4, 2015
P2, N=25, Not yet recruiting, Sponsor: Rigel Pharmaceuticals
- Trial completion, Trial primary completion date: Closed-loop Control of Glucose Levels (Artificial Pancreas) for 60 Hours in Adults With Type 1 Diabetes (clinicaltrials.gov) - May 4, 2015
P2, N=23, Completed, Sponsor: Institut de Recherches Cliniques de Montreal
Active, not recruiting --> Recruiting | N=12 --> 24 | Trial primary completion date: May 2015 --> Sep 2015 Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Apr 2015
- Trial completion: Closed-loop Control of Glucose Levels (Artificial Pancreas) During Exercise in Adults With Type 1 Diabetes (clinicaltrials.gov) - May 4, 2015
P2, N=15, Completed, Sponsor: Institut de Recherches Cliniques de Montreal
Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Apr 2015 Recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, HEOR: Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment) (clinicaltrials.gov) - May 1, 2015
P=N/A, N=2000, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Trial primary completion date: Apr 2015 --> Sep 2015
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, HEOR: AGIL: Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 1, 2015
P=N/A, N=4500, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Apr 2015 --> Sep 2015 Trial primary completion date: Dec 2018 --> May 2017
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - May 1, 2015
P=N/A, N=80, Recruiting, Sponsor: AbbVie
Trial primary completion date: Dec 2018 --> May 2017 N=140 --> 80
- Trial completion: APCam09: Automated Closed-loop in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - May 1, 2015
P=N/A, N=13, Completed, Sponsor: University of Cambridge
N=140 --> 80 Recruiting --> Completed
- || decernotinib (VX-509) / Vertex
Trial completion, Trial primary completion date: A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - May 1, 2015
P2/3, N=39, Completed, Sponsor: Vertex Pharmaceuticals Incorporated
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Jul 2014
- |||| Orencia (abatacept) / BMS
Trial primary completion date: MTX-IR: Methotrexate-Inadequate Response Autoinjector Device Sub Study (clinicaltrials.gov) - May 1, 2015
P3, N=120, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Jul 2014 Trial primary completion date: Mar 2014 --> Jul 2014